EGFR and cancer: The HBV−/drinker cohort contained a greater proportion of cancer pathways (EGFR tyrosine kinase inhibitor resistance, Rap1 signaling pathway, cellular senescence and PD-L1 expression and PD-1 checkpoint pathway in cancer) than immune pathways (cytokine-cytokine receptor interactions).